IN2012DN01231A - - Google Patents

Download PDF

Info

Publication number
IN2012DN01231A
IN2012DN01231A IN1231DEN2012A IN2012DN01231A IN 2012DN01231 A IN2012DN01231 A IN 2012DN01231A IN 1231DEN2012 A IN1231DEN2012 A IN 1231DEN2012A IN 2012DN01231 A IN2012DN01231 A IN 2012DN01231A
Authority
IN
India
Prior art keywords
jnk
compounds
disclosed
compositions
formulations
Prior art date
Application number
Other languages
English (en)
Inventor
Leyi Gong
Xiaochun Han
Ferenc Makra
Wylie Solang Palmer
Lubica Raptova
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IN2012DN01231A publication Critical patent/IN2012DN01231A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IN1231DEN2012 2009-08-10 2010-08-06 IN2012DN01231A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23252209P 2009-08-10 2009-08-10
PCT/EP2010/061476 WO2011018417A1 (en) 2009-08-10 2010-08-06 Inhibitors of jnk

Publications (1)

Publication Number Publication Date
IN2012DN01231A true IN2012DN01231A (zh) 2015-05-15

Family

ID=42710723

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1231DEN2012 IN2012DN01231A (zh) 2009-08-10 2010-08-06

Country Status (15)

Country Link
US (1) US8536172B2 (zh)
EP (1) EP2464640A1 (zh)
JP (1) JP5784604B2 (zh)
KR (1) KR101506318B1 (zh)
CN (1) CN102471319B (zh)
AR (1) AR077820A1 (zh)
AU (1) AU2010283769B2 (zh)
BR (1) BR112012003059A2 (zh)
CA (1) CA2768749A1 (zh)
IL (1) IL217756A0 (zh)
IN (1) IN2012DN01231A (zh)
MX (1) MX2012001449A (zh)
SG (1) SG178321A1 (zh)
TW (1) TW201109336A (zh)
WO (1) WO2011018417A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012030814A2 (pt) * 2010-06-04 2019-09-24 Hoffmann La Roche inibidores de jnk
CN104768946B (zh) 2012-07-20 2017-05-03 克里弗生物科学公司 作为p97复合物的抑制剂的稠合嘧啶
CA2903275A1 (en) * 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
SG11201608242XA (en) 2014-04-04 2016-10-28 Syros Pharmaceuticals Inc Inhibitors of cyclin-dependent kinase 7 (cdk7)
EP3234110B1 (en) 2014-12-18 2024-02-28 President and Fellows of Harvard College METHODS FOR GENERATING STEM CELL-DERIVED ß CELLS AND USES THEREOF

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5325783B2 (ja) * 2006-09-08 2013-10-23 エフ．ホフマン−ラ ロシュ アーゲー ベンゾトリアゾールキナーゼモジュレーター
CN101547917A (zh) * 2006-12-08 2009-09-30 霍夫曼-拉罗奇有限公司 用作jnk调节剂的取代的嘧啶类化合物及它们的应用

Also Published As

Publication number Publication date
KR20120055645A (ko) 2012-05-31
AU2010283769A1 (en) 2012-02-09
CN102471319A (zh) 2012-05-23
SG178321A1 (en) 2012-03-29
WO2011018417A1 (en) 2011-02-17
JP5784604B2 (ja) 2015-09-24
MX2012001449A (es) 2012-03-26
TW201109336A (en) 2011-03-16
CN102471319B (zh) 2014-06-18
AR077820A1 (es) 2011-09-28
IL217756A0 (en) 2012-03-29
AU2010283769B2 (en) 2015-09-17
US8536172B2 (en) 2013-09-17
CA2768749A1 (en) 2011-02-17
KR101506318B1 (ko) 2015-03-26
JP2013501746A (ja) 2013-01-17
EP2464640A1 (en) 2012-06-20
BR112012003059A2 (pt) 2016-08-02
US20110034470A1 (en) 2011-02-10

Similar Documents

Publication Publication Date Title
TW200744586A (en) Therapeutic compounds
MX2011007750A (es) Composiciones y metodos para inhibicion de la ruta jak.
MX348024B (es) Compuestos de adamantilo.
MX2009006195A (es) Compuestos basados en 4-fenil-6-(2,2,2-trifluoro-1-feniletoxi)piri midina y metodos de su uso.
MX2020009397A (es) Composiciones y metodos para inhibicion de la via jak.
MX2009011754A (es) Inhibidores de enzima de diacilglicerol o-aciltransferasa tipo 1.
MX2012002633A (es) Aminotetrahidropiranos como inhibidores de la dipeptidil peptidasa iv para el tratamiento prevencion de la diabetes.
MX2009013353A (es) Compuestos activadores de telomerasa y metodos para su uso.
MY153057A (en) Tryclic compounds,compositions and methods
MX2011007496A (es) Nuevas bencensulfonamidas como bloqueadores del canal de calcio.
WO2006093547A3 (en) Novel lipoxygenase inhibitors
MX2013004329A (es) 6-amino-nicotinamidas sustituidas como moduladores de kcnq2/3.
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
ZA201006782B (en) Novel p2x7r antagonists and thier use
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
WO2010124121A8 (en) Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitor
MX337849B (es) Composiciones y metodos para inhibicion de la via jak.
MX2009011753A (es) Inhibidores de enzima de diacilglicerol o-aciltransferasa tipo 1.
IN2012DN03846A (zh)
MX2014000374A (es) Compuesto de aminometil quinolona.
IN2012DN01231A (zh)
MX342119B (es) 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
UA101961C2 (en) 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form
WO2010065861A3 (en) Inhibitors of bace 1 and methods for treating alzheimer's disease
DE602008002598D1 (en) Cyclohexylderivate